ClearPoint Neuro showcases a 41% revenue increase and strategic expansions in biologics and capital equipment sectors.
First Quarter Revenue Growth +41%; Record Revenue AchievedSOLANA BEACH, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights Reported quarterly revenue of $7.6 million, a 41% year-over-year increase;Increased biologics and drug delivery revenue
SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting to be held in Baltimore, MD from May 7-11. The following original research abstracts will be presented at the Poster Session: De-Risking Clinical Trials Le